Drug Trial Radar · NCT06365424
Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
117
Planned (sponsor's estimate)
Start
Apr 8, 2017
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Xijing Hospital of Digestive DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Open Label Long-Term Study to Evaluate the Safety and Effectiveness of Fenofibrate in Subjects with Primary Biliary Cholangitis (PBC)
Conditions
- Primary Biliary Cholangitis
Interventions
FenofibrateDrug
Fenofibrate (200 mg/day)
UDCADrug
Ursodeoxycholic acid (13-15 mg/kg/day)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent adverse events (TEAEs)Time frame: Through study completion, up to 120 Months
- Percentage of patients with biochemical responseTime frame: Through study completion, up to 120 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xijing Hospital
Xi'an, Shaanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.